CRISPR Could Switch Off Chronic Pain Without Opioids
By Emily Mullin,
Future Human
| 03. 10. 2021
In 2006, scientists described the curious case of a Pakistani boy who seemed immune to pain. The 10-year-old street performer amazed audiences by walking on burning coals and stabbing himself with knives without flinching.
His resistance to pain later led him to jump off a building to impress his friends. Tragically, he died from the resulting injuries. He had just turned 14.
Several of the boy’s relatives had never experienced pain either. When researchers collected samples of their blood and analyzed their genes, they found that they all harbored mutations in a gene called SCN9A. Two other families in northern Pakistan were found to have similar mutations that made them unable to feel pain.
Now, a biotech startup wants to mimic this mutation to treat people with chronic pain. In a new paper published March 10 in Science Translational Medicine, researchers used the gene-editing technique CRISPR to successfully repress the gene and increase pain tolerance in mice. The effects lasted up to 44 weeks. If it proves safe in people, the therapy could offer an alternative to opioids...
Related Articles
By Katie Hunt, CNN | 07.30.2025
Scientists are exploring ways to mimic the origins of human life without two fundamental components: sperm and egg.
They are coaxing clusters of stem cells – programmable cells that can transform into many different specialized cell types – to form...
By Ewen Callaway, Nature | 08.04.2025
For months, researchers in a laboratory in Dallas, Texas, worked in secrecy, culturing grey-wolf blood cells and altering the DNA within. The scientists then plucked nuclei from these gene-edited cells and injected them into egg cells from a domestic dog ...
By Kristel Tjandra, Genetic Engineering & Biotechnology News | 07.30.2025
CRISPR has taken the bioengineering world by storm since its first introduction. From treating sickle cell diseases to creating disease-resistant crops, the technology continues to boast success on various fronts. But getting CRISPR experiments right in the lab isn’t simple...
By Arthur Caplan and James Tabery, Scientific American | 07.28.2025
An understandable ethics outcry greeted the June announcement of a software platform that offers aspiring parents “genetic optimization” of their embryos. Touted by Nucleus Genomics’ CEO Kian Sadeghi, the $5,999 service, dubbed “Nucleus Embryo,” promised optimization of...